Monopar Therapeutics (MNPR) Common Equity (2016 - 2020)

Monopar Therapeutics' Common Equity history spans 5 years, with the latest figure at $17.5 million for Q3 2020.

  • For Q3 2020, Common Equity rose 278.2% year-over-year to $17.5 million; the TTM value through Sep 2020 reached $17.5 million, up 278.2%, while the annual FY2019 figure was $12.6 million, 82.53% up from the prior year.
  • Common Equity for Q3 2020 was $17.5 million at Monopar Therapeutics, up from $12.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $17.5 million in Q3 2020 and bottomed at $2.8 million in Q4 2016.
  • The 5-year median for Common Equity is $8.1 million (2018), against an average of $8.8 million.
  • The largest annual shift saw Common Equity plummeted 38.95% in 2019 before it skyrocketed 278.2% in 2020.
  • A 5-year view of Common Equity shows it stood at $2.8 million in 2016, then skyrocketed by 239.78% to $9.6 million in 2017, then dropped by 28.08% to $6.9 million in 2018, then surged by 82.53% to $12.6 million in 2019, then skyrocketed by 38.52% to $17.5 million in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Common Equity are $17.5 million (Q3 2020), $12.2 million (Q2 2020), and $12.4 million (Q1 2020).